| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Total revenues | $56.4M+107.4% | $27.2M-52.8% | $57.5M+26.8% | $45.4M | — | $15.6M-17.2% | $18.8M |
| Total cost of revenues | $62.3M+61.5% | $38.6M-17.0% | $46.5M-7.7% | $50.4M+9.9% | $45.8M+72.1% | $26.6M+16.7% | $22.8M |
| Gross profit | $142.6M+8.0% | $132.1M-6.1% | $140.7M+39.3% | $101.0M+54.0% | $65.6M+3.4% | $63.5M+29.3% | $49.1M |
| Research and development | $173.1M-14.2% | $201.8M+11.0% | $181.8M+43.8% | $126.4M+39.0% | $90.9M+40.5% | $64.7M+64.2% | $39.4M |
| Sales and marketing | $41.0M+2.6% | $39.9M+7.2% | $37.2M+21.5% | $30.6M+38.3% | $22.1M+24.5% | $17.8M-16.7% | $21.4M |
| General and administrative | $95.4M-4.3% | $99.7M+0.5% | $99.1M+9.2% | $90.8M+41.9% | $64.0M+52.8% | $41.9M+54.9% | $27.0M |
| Total operating expenses | $309.5M-9.3% | $341.4M+7.3% | $318.1M+28.4% | $247.8M+40.0% | $177.1M+42.3% | $124.4M+41.7% | $87.8M |
| Loss from operations | -$166.9M+20.3% | -$209.3M-17.9% | -$177.4M-20.9% | -$146.8M-31.7% | -$111.4M-82.9% | -$60.9M-57.3% | -$38.7M |
| Gain on equity investments | $0 | $0-100.0% | $147.2M+1144.9% | $11.8M+764.0% | -$1.8M-143.4% | $4.1M+335.6% | $943K |
| Change in fair value of equity investments | $48.2M+747.7% | $5.7M-89.4% | $53.5M+395.6% | -$18.1M-259.2% | $11.4M | — | — |
| Other income | $16.4M-8.4% | $17.9M-9.1% | $19.7M+398.2% | $4.0M+274.0% | $1.1M-53.1% | $2.3M | — |
| Total other income | $64.6M+173.8% | $23.6M-89.3% | $220.4M+9656.2% | -$2.3M-121.7% | $10.6M-69.3% | $34.6M+171.7% | $12.7M |
| (Loss) income before income taxes | -$102.3M+44.9% | -$185.7M-532.7% | $42.9M+128.8% | -$149.1M-47.9% | -$100.8M-283.4% | -$26.3M-1.2% | -$26.0M |
| Income tax expense | $939K-33.5% | $1.4M-35.8% | $2.2M+3390.5% | $63K-84.7% | $411K+19.1% | $345K+218.6% | -$291K |
| Net (loss) income | -$103.3M+44.8% | -$187.1M-559.5% | $40.7M+127.3% | -$149.2M-48.6% | -$100.4M-310.4% | -$24.5M+0.4% | -$24.6M |
| Net (loss) income per share attributable to common and limited common stockholders, basic (in USD per share) | -$1410.00+45.1% | -$2570.00-550.9% | $570.00+127.1% | -$2100.00-47.9% | -$1420.00-246.3% | -$410.00 | — |
| Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, basic (in shares) | $73443298000.00+1.1% | $72670295000.00+1.2% | $71776301000.00+0.8% | $71173419000.00+0.8% | $70594950000.00+17.6% | $60024658000.00 | — |
| Net (loss) income per share of common and limited common stockholders, diluted (in USD per share) | -$1410.00+45.1% | -$2570.00-575.9% | $540.00+125.7% | -$2100.00-47.9% | -$1420.00-246.3% | -$410.00 | — |
| Weighted average shares used to compute net (loss) income per share of common and limited common stockholders, diluted (in shares) | $73443298000.00+1.1% | $72670295000.00-3.1% | $74986816000.00+5.4% | $71173419000.00+0.8% | $70594950000.00+17.6% | $60024658000.00 | — |
| Software products and services | |||||||
| Drug discovery | |||||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.